Revolution Medicines Inc. (RVMD)
RVMD Stock Tumbles as MRK Reportedly Withdraws Buyout Offer
Revolution Medicines stock tanks after a WSJ report said Merck has withdrawn from buyout talks over price.
Revolution Medicines, Inc. (RVMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Revolution Medicines, Inc. (RVMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Revolution Medicines: "Strong Buy" As Acquisition Prospects Continue To Circle
Revolution Medicines (RVMD) remains a "Strong Buy", driven by advanced RAS [ON] inhibitor programs and robust clinical progress, notably with Daraxonrasib. Company's phase 3 RASolute-302 trial in metastatic PDAC RAS-mutant patients is a major catalyst, with data expected in 2026 and significant expansion potential. Buyout interest from major pharma, including rumored $28–32B bids, underscores RVMD's strategic value and enhances upside optionality.
Revolution Medicines Stock Soars. Takeover Buzz Grows, Another Suitor Emerges.
Revolution Medicines stock was soaring again early Friday after a report that Merck is in talks to buy the cancer-drug biotech for up to $32 billion.
RVMD Stock Hits a Record High on Rumored Takeover Interest
Revolution Medicines shares jump nearly 29% to a record high after a WSJ report said AbbVie showed takeover interest, a claim the pharma giant later denied.
Revolution Medicines (RVMD) Up 27.9% Since Last Earnings Report: Can It Continue?
Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock?
Revolution Medicines, Inc. (RVMD) Presents at Jefferies London Healthcare Conference 2025 Transcript
Revolution Medicines, Inc. ( RVMD ) Jefferies London Healthcare Conference 2025 November 18, 2025 4:30 AM EST Company Participants Mark Goldsmith - CEO, President & Chairman Conference Call Participants Yuxi Dong - Jefferies LLC, Research Division Presentation Yuxi Dong Jefferies LLC, Research Division Good morning, everyone. Let's get started.
Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript
Revolution Medicines, Inc. ( RVMD ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 11, 2025 9:00 AM EST Company Participants Mark Goldsmith - CEO, President & Chairman Conference Call Participants Michael Schmidt - Guggenheim Securities, LLC, Research Division Presentation Michael Schmidt Guggenheim Securities, LLC, Research Division All right. So we'll get started right away.
Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil
RVMD posts a wider Q3 loss as rising R&D and administrative costs weigh, while its RAS(ON) pipeline advances toward key 2026 data.
Revolution Medicines, Inc. (RVMD) Q3 2025 Earnings Call Transcript
Revolution Medicines, Inc. ( RVMD ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Ryan Asay - Senior Vice President of Corporate Affairs Mark Goldsmith - CEO, President & Chairman Wei Lin - Chief Medical Officer Jack Anders - Chief Financial Officer Alan Bart Sandler - Chief Development Officer Anthony Mancini Stephen Kelsey - President of Research & Development Conference Call Participants Jonathan Chang - Leerink Partners LLC, Research Division Yue-Wen Zhu - LifeSci Capital, LLC, Research Division Michael Schmidt - Guggenheim Securities, LLC, Research Division Morgan Lamberti - Goldman Sachs Group, Inc., Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Marc Frahm - TD Cowen, Research Division Leonid Timashev - RBC Capital Markets, Research Division Jenna Li - Jefferies LLC, Research Division Asthika Goonewardene - Truist Securities, Inc., Research Division Alec Stranahan - BofA Securities, Research Division Joseph Catanzaro - Mizuho Securities USA LLC, Research Division Laura Prendergast - Stifel, Nicolaus & Company, Incorporated, Research Division Ami Fadia - Needham & Company, LLC, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Revolution Medicines Q3 2025 Earnings Conference Call.
Revolution Medicines: Shares Soar On Pancreatic Cancer Study Win - I'm Sold
Revolution Medicines, Inc. shares surged on strong Phase 1 data for daraxonrasib in metastatic pancreatic cancer, showing high response and disease control rates. Daraxonrasib demonstrated superior efficacy and durability versus current standards, with promising results in both monotherapy and combination with gemcitabine. RVMD secured a $2 billion deal with Royalty Pharma, ensuring robust funding as it advances to a pivotal Phase 3 trial targeting a paradigm shift in PDAC treatment.
Revolution Medicines, Inc. (RVMD) Discussion On Metastatic Pancreatic Cancer Update Call (Transcript)
Revolution Medicines, Inc. Metastatic Pancreatic Cancer Update Call September 10, 2025 5:00 PM EDT Company Participants Ryan Asay - Senior Vice President of Corporate Affairs Mark Goldsmith - CEO, President & Chairman Stephen Kelsey - President of Research & Development Wei Lin - Chief Medical Officer Conference Call Participants Albert Agustinus - Leerink Partners LLC, Research Division Michael Schmidt - Guggenheim Securities, LLC, Research Division Yue-Wen Zhu - LifeSci Capital, LLC, Research Division Morgan Lamberti - Goldman Sachs Group, Inc., Research Division Eliana Merle - UBS Investment Bank, Research Division Marc Frahm - TD Cowen, Research Division Kelsey Goodwin - Piper Sandler & Co., Research Division Asthika Goonewardene - Truist Securities, Inc., Research Division Presentation Operator Thank you for standing by, and welcome to Revolution Medicines Conference Call. Today's program is being recorded.
